Deals
-
Humanigen Announces Cooperative Research and Development Agreement with the U.S. government to Develop Lenzilumab for COVID-19
November 6, 2020 The Cooperative Research and Development Agreement (CRADA) with the Department of Defense (DoD) supports the development of lenzilumab as a potential treatment for patients with Covid-19 Humanigen...
6 Nov 2020
-
5 Nov 2020
Merck to Acquire VelosBio for $2.75bn
November 5, 2020 KENILWORTH, N.J. & SAN DIEGO--(BUSINESS WIRE)- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and VelosBio Inc. today announced that the companies have entered into a definitive agreement pursuant to which...
-
2 Nov 2020
Sanofi Offers to Acquire Kiadis, a Clinical-stage Company Developing Cell-based Immunotherapy Products
November 2, 2020 PARIS and AMSTERDAM – Sanofi and Kiadis, a clinical-stage biopharmaceutical company developing innovative 'off the shelf' natural killer (NK) cell based medicines for the treatment of life-threatening diseases, entered into a de...
-
28 Oct 2020
Sanofi and GSK to Support COVAX with 200 Million Doses of Adjuvanted, Recombinant Protein-based COVID-19 Vaccine
October 28, 2020 PARIS and LONDON – Sanofi and GSK have signed a Statement of Intent with Gavi, the legal administrator of the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of eventual COVID-19...
-
27 Oct 2020
Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need for New Treatments
27 October 2020 Sobi obtains global co-development and exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, a targeted C3 therapy. Apellis retains U.S. co...
-
26 Oct 2020
Bayer Acquires Asklepios BioPharmaceutical to Broaden Innovation Base in Cell and Gene Therapy
October 26, 2020 Berlin, Germany, October 26, 2020 – Bayer AG today announced the acquisition of Asklepios BioPharmaceutical, Inc. (AskBio), a US-headquartered biopharmaceutical company specialized in the...
-
23 Oct 2020
Gilead Sciences Completes Acquisition of Immunomedics, Inc.
October 23, 2020 FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire Immunomedics, Inc. (Nasdaq: I...
-
14 Oct 2020
Exscientia and Blue Oak Pharmaceuticals Announce Collaboration to Rapidly Discover Innovative Treatments for CNS Disorders
October 14, 2020 Blue Oak Pharmaceuticals, an innovator in the discovery of transformative CNS drugs, and Exscientia, a clinical-stage Artificial Intelligence (AI) drug-discovery company, announced to...
-
13 Oct 2020
Twist Bioscience and Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Therapies
13 October 2020 Partnership Combines Twist's Leadership in DNA Synthesis and Synthetic Biology with Neogene's Expertise in Personalized Engineered T Cell Therapies SOUTH SAN FRANCISCO, Calif. and AMSTER...
Join Our Newsletter for Free
